MCID: CHL018
MIFTS: 49

Childhood Medulloblastoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Childhood Medulloblastoma

MalaCards integrated aliases for Childhood Medulloblastoma:

Name: Childhood Medulloblastoma 12 52 15
Medulloblastoma, Childhood 52 71
Pediatric Medulloblastoma 12
Medulloblastoma Childhood 54

Classifications:



External Ids:

Disease Ontology 12 DOID:3869
MeSH 43 D008527
NCIt 49 C3997
UMLS 71 C0278510

Summaries for Childhood Medulloblastoma

MalaCards based summary : Childhood Medulloblastoma, also known as medulloblastoma, childhood, is related to large cell medulloblastoma and nodular medulloblastoma, and has symptoms including vomiting, gait ataxia and headache. An important gene associated with Childhood Medulloblastoma is CRNDE (Colorectal Neoplasia Differentially Expressed), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Temozolomide and Lomustine have been mentioned in the context of this disorder. Affiliated tissues include brain, breast and lung, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Childhood Medulloblastoma

Diseases related to Childhood Medulloblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 306)
# Related Disease Score Top Affiliating Genes
1 large cell medulloblastoma 30.4 SUFU MYCN MYC
2 nodular medulloblastoma 30.4 SUFU PTCH1 MYCN GLI2 CTNNB1
3 greig cephalopolysyndactyly syndrome 30.3 SUFU PTCH1 GLI2
4 rhabdoid cancer 30.0 TP53 SMARCA4 CCND1
5 adult medulloblastoma 29.9 SUFU PTCH1 MYCN GLI2 DDX3X
6 familial adenomatous polyposis 29.9 TP53 MYC CTNNB1 CCND1
7 atypical teratoid rhabdoid tumor 29.7 TP53 SMARCA4 ERBB4 CTNNB1 CCND1
8 basal cell nevus syndrome 29.6 TP53 SUFU PTCH1 MYCN MYC GLI2
9 ovarian disease 29.5 TP53 MYC ERBB2 EGFR CCND1
10 malignant glioma 29.3 TP53 TERT EGFR CRNDE
11 brain cancer 29.1 TP53 TERT PTCH1 PDGFRA NTRK3 MYCN
12 rhabdomyosarcoma 29.1 TP53 PTCH1 PDGFRA MYCN MYC EGFR
13 retinoblastoma 29.1 TP53 SMARCA4 MYCN MYC CCND1
14 basal cell carcinoma 29.0 TP53 TERT SUFU PTCH1 MYCN GLI2
15 nasopharyngeal carcinoma 28.8 TP53 TERT MYC ERBB2 EGFR CTNNB1
16 glioma 28.7 TP53 PDGFRA ERBB2 EGFR CRNDE CCND1
17 li-fraumeni syndrome 28.7 TP53 TERT SUFU PTCH1 MYCN MYC
18 meningioma, familial 28.7 TP53 TERT SUFU PTCH1 MYC ERBB2
19 melanoma 28.3 TP53 TERT PDGFRA MYC ERBB4 ERBB2
20 neuroblastoma 28.2 TP53 TERT SMARCA4 PTCH1 NTRK3 MYCN
21 glioblastoma multiforme 28.1 TP53 TERT PDGFRA MYCN MYC ERBB3
22 leukemia, acute myeloid 28.0 TP53 TERT PDGFRA MYCN MYC KMT2D
23 medulloblastoma 27.7 TP53 TERT SUFU SMARCA4 PTCH1 PDGFRA
24 gastric cancer 27.5 TP53 TERT SMARCA4 PTCH1 MYC ERBB3
25 hepatocellular carcinoma 27.1 TP53 TERT SMARCA4 PTCH1 MYC ERBB3
26 ovary leiomyosarcoma 10.6 SUFU PTCH1
27 holoprosencephaly, recurrent infections, and monocytosis 10.6 PTCH1 GLI2
28 cerebral primitive neuroectodermal tumor 10.5 MYCN MYC
29 vulvar intraepithelial neoplasia 10.5 TP53 CTNNB1
30 melanotic medulloblastoma 10.5 SUFU PTCH1 MYCN
31 anal carcinoma in situ 10.5 TP53 MYC
32 squamous blepharitis 10.5 ERBB4 ERBB3
33 vulva basal cell carcinoma 10.5 MYC ERBB2
34 richter's syndrome 10.4 TP53 MYCN MYC
35 calcifying epithelial odontogenic tumor 10.4 TP53 PTCH1 GLI2
36 microform holoprosencephaly 10.4 SUFU PTCH1 GLI2
37 lung acinar adenocarcinoma 10.4 MYC EGFR CTNNB1
38 connective tissue benign neoplasm 10.4 TP53 PTCH1 CTNNB1
39 micronodular basal cell carcinoma 10.4 TP53 PTCH1 GLI2
40 gastric papillary adenocarcinoma 10.4 TP53 ERBB2
41 microcystic stromal tumor 10.4 CTNNB1 CCND1
42 esophageal leukoplakia 10.4 TP53 CCND1
43 her2-receptor positive breast cancer 10.4 ERBB4 ERBB2
44 central nervous system benign neoplasm 10.4 TP53 MYCN CTNNB1
45 acneiform dermatitis 10.4 ERBB4 EGFR
46 acinar cell carcinoma 10.4 TP53 NTRK3 CTNNB1
47 b cell prolymphocytic leukemia 10.4 TP53 MYC
48 esophageal basaloid squamous cell carcinoma 10.4 TP53 EGFR
49 breast squamous cell carcinoma 10.4 TP53 ERBB2
50 basosquamous carcinoma 10.4 TP53 PTCH1

Graphical network of the top 20 diseases related to Childhood Medulloblastoma:



Diseases related to Childhood Medulloblastoma

Symptoms & Phenotypes for Childhood Medulloblastoma

UMLS symptoms related to Childhood Medulloblastoma:


vomiting, gait ataxia, headache

GenomeRNAi Phenotypes related to Childhood Medulloblastoma according to GeneCards Suite gene sharing:

26 (show all 14)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.2 EGFR
2 Decreased viability GR00106-A-0 10.2 ERBB3
3 Decreased viability GR00173-A 10.2 PDGFRA
4 Decreased viability GR00221-A-1 10.2 EGFR PDGFRA
5 Decreased viability GR00221-A-2 10.2 ERBB3 NTRK3
6 Decreased viability GR00221-A-3 10.2 ERBB2 PDGFRA
7 Decreased viability GR00221-A-4 10.2 EGFR ERBB2 ERBB3 NTRK3 PDGFRA
8 Decreased viability GR00301-A 10.2 ERBB3
9 Decreased viability GR00342-S-2 10.2 ERBB3
10 Decreased viability GR00342-S-3 10.2 ERBB3
11 Decreased viability GR00402-S-2 10.2 EGFR ERBB2 ERBB3 NTRK3 PDGFRA
12 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.65 CTNNB1 EGFR ERBB2 ERBB4 NTRK3
13 Increased cell death HMECs cells GR00103-A-0 9.43 CTNNB1 EGFR ERBB3 ERBB4 MYC TP53
14 Increased cell viability after pRB stimulation GR00230-A-1 8.92 EGFR ERBB2 ERBB3 ERBB4

MGI Mouse Phenotypes related to Childhood Medulloblastoma:

45 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.53 CCND1 CTNNB1 DDX3X EGFR ERBB2 ERBB3
2 cellular MP:0005384 10.52 CCND1 CTNNB1 DDX3X EGFR ERBB2 ERBB3
3 growth/size/body region MP:0005378 10.51 CCND1 CTNNB1 DDX3X EGFR ERBB2 ERBB3
4 behavior/neurological MP:0005386 10.47 BATF2 CCND1 CTNNB1 ERBB2 ERBB3 ERBB4
5 embryo MP:0005380 10.47 CTNNB1 DDX3X EGFR ERBB2 ERBB3 ERBB4
6 mortality/aging MP:0010768 10.47 BATF2 CCND1 CTNNB1 DDX3X EGFR ERBB2
7 craniofacial MP:0005382 10.46 CCND1 CTNNB1 EGFR ERBB2 ERBB4 GLI2
8 homeostasis/metabolism MP:0005376 10.46 CCND1 CTNNB1 DDX3X EGFR ERBB2 ERBB3
9 digestive/alimentary MP:0005381 10.45 CCND1 CTNNB1 EGFR ERBB2 ERBB3 GLI2
10 endocrine/exocrine gland MP:0005379 10.4 CCND1 CTNNB1 EGFR ERBB2 ERBB3 ERBB4
11 immune system MP:0005387 10.39 BATF2 CCND1 CTNNB1 EGFR ERBB3 ERBB4
12 nervous system MP:0003631 10.39 CCND1 CTNNB1 DDX3X EGFR ERBB2 ERBB3
13 hematopoietic system MP:0005397 10.38 CCND1 CTNNB1 EGFR ERBB4 KMT2D MYC
14 integument MP:0010771 10.35 CCND1 CTNNB1 EGFR ERBB2 ERBB3 ERBB4
15 muscle MP:0005369 10.32 CTNNB1 DDX3X EGFR ERBB2 ERBB3 ERBB4
16 normal MP:0002873 10.3 CCND1 CTNNB1 DDX3X EGFR ERBB2 ERBB3
17 neoplasm MP:0002006 10.27 CCND1 CTNNB1 EGFR ERBB2 ERBB3 KMT2D
18 limbs/digits/tail MP:0005371 10.26 CTNNB1 EGFR ERBB2 GLI2 MYC MYCN
19 hearing/vestibular/ear MP:0005377 10.18 CTNNB1 EGFR GLI2 KMT2D MYC NTRK3
20 liver/biliary system MP:0005370 10.11 CTNNB1 EGFR MYC MYCN SMARCA4 SUFU
21 no phenotypic analysis MP:0003012 10.1 CTNNB1 EGFR GLI2 MYC MYCN NTRK3
22 reproductive system MP:0005389 10.1 CCND1 CTNNB1 DDX3X EGFR ERBB2 ERBB4
23 respiratory system MP:0005388 10.06 CCND1 CTNNB1 EGFR ERBB2 ERBB3 ERBB4
24 pigmentation MP:0001186 9.97 CTNNB1 EGFR ERBB3 MYC PDGFRA PTCH1
25 skeleton MP:0005390 9.8 CCND1 CTNNB1 EGFR ERBB2 GLI2 KMT2D
26 vision/eye MP:0005391 9.32 CCND1 CTNNB1 EGFR GLI2 MYCN NTRK3

Drugs & Therapeutics for Childhood Medulloblastoma

Drugs for Childhood Medulloblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 195)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Temozolomide Approved, Investigational Phase 3 85622-93-1 5394
2
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
4
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
5
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
6
Ondansetron Approved Phase 3 99614-02-5 4595
7
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
8
Histamine Approved, Investigational Phase 3 51-45-6 774
9
Cyproheptadine Approved Phase 3 129-03-3 2913
10
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
11
Emodepside Investigational, Vet_approved Phase 3 155030-63-0
12 Anti-Bacterial Agents Phase 3
13 Antitubercular Agents Phase 3
14 Antioxidants Phase 3
15 Chelating Agents Phase 3
16 sodium thiosulfate Phase 3
17 Antidotes Phase 3
18 Hormones Phase 3
19 BB 1101 Phase 3
20 Calcium, Dietary Phase 3
21 Autonomic Agents Phase 3
22 Emetics Phase 3
23 Antiemetics Phase 3
24 Neurotransmitter Agents Phase 3
25 Gastrointestinal Agents Phase 3
26 Histamine H1 Antagonists Phase 3
27 Antipruritics Phase 3
28
Histamine Phosphate Phase 3 51-74-1 65513
29 Histamine Antagonists Phase 3
30 Anti-Allergic Agents Phase 3
31 Serotonin Antagonists Phase 3
32 Serotonin Agents Phase 3
33
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
34
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
35
Megestrol acetate Approved, Investigational, Vet_approved Phase 2 595-33-5 11683
36
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
37
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
38
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
39
Phenylacetic acid Approved Phase 2 103-82-2 999
40
Carmustine Approved, Investigational Phase 2 154-93-8 2578
41
Tamoxifen Approved Phase 2 10540-29-1 2733526
42
Sodium citrate Approved, Investigational Phase 2 68-04-2
43
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
44
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
45
Procarbazine Approved, Investigational Phase 2 671-16-9 4915
46
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
47
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
48
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
49
Gemcitabine Approved Phase 2 95058-81-4 60750
50
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 446556 60843

Interventional clinical trials:

(show top 50) (show all 99)
# Name Status NCT ID Phase Drugs
1 A Prospective Randomised Controlled Trial Of Hyperfractionated Versus Conventionally Fractionated Radiotherapy In Standard Risk Medulloblastoma Unknown status NCT00053872 Phase 3 cisplatin;lomustine;vincristine sulfate
2 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III] Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
3 Phase III Prospective Randomized Study of Craniospinal RT Followed by One of Two Adjuvant Chemotherapy Regimens (CCNU, CDDP, VCR OR CPM, CDDP, VCR) for Newly-Diagnosed Average Risk MedulloblastomaMEDULLOBLASTOMA Completed NCT00002875 Phase 3 cisplatin;cyclophosphamide;lomustine;mesna;vincristine sulfate
4 A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children Completed NCT00716976 Phase 3 sodium thiosulfate
5 Systemic Chemotherapy, Second Look Surgery and Conformal Radiation Therapy Limited to the Posterior Fossa and Primary Site for Children >/= to 8 Months and <3 Years With Non-metastatic Medulloblastoma: A Children&Apos;s Oncology Group Phase III Study Completed NCT00006461 Phase 3 cisplatin;cyclophosphamide;vincristine sulfate;etoposide
6 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
7 A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial Completed NCT00085735 Phase 3 Cisplatin;Cyclophosphamide;Lomustine;Vincristine Sulfate
8 A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children <36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate Completed NCT00336024 Phase 3 etoposide;cyclophosphamide;cisplatin;carboplatin;thiotepa;methotrexate;leucovorin calcium;vincristine sulfate
9 Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Active, not recruiting NCT00085202 Phase 3 cisplatin;cyclophosphamide;vincristine
10 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
11 Management of Children Aged Less Than 3 Years With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
12 Hyperfractionated Accelerated Radiotherapy (HART) With Chemotherapy (Cisplatin, CCNU, Vincristine) for Metastatic (M1-3) Medulloblastoma Unknown status NCT00276666 Phase 2 cisplatin;lomustine;vincristine sulfate
13 The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
14 Phase II Study of Arsenic Trioxide in Neuroblastoma and Other Pediatric Solid Tumors Completed NCT00024258 Phase 2 arsenic trioxide
15 A PHASE II STUDY OF DOCETAXEL (TAXOTERE) (NSC# 628503) IN CHILDREN WITH RECURRENT SOLID TUMORS Completed NCT00002825 Phase 2 docetaxel
16 A Phase I/II Trial of Temodar in Pediatric Patients and Young Adults With High-Risk or Recurrent Solid Tumors Completed NCT00005952 Phase 1, Phase 2 temozolomide
17 A Phase II Study of Oxaliplatin in Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors and Atypical Teratoid Rhabdoid Tumors Completed NCT00047177 Phase 2 Oxaliplatin
18 Phase II Study of Phenylacetate in Pediatric Patients With Central Nervous System Tumors Completed NCT00003241 Phase 2 phenylacetate
19 PHASE I STUDY OF ANTI-TENASCIN MONOCLONAL ANTIBODY 131I 81C6 VIA SURGICALLY CREATED CYSTIC RESECTION CAVITY IN THE TREATMENT OF PATIENTS WITH PRIMARY OR METASTATIC MALIGNANT BRAIN TUMORS Completed NCT00002752 Phase 1, Phase 2
20 Dose-Intensive Melphalan and Cyclophosphamide With Autologous Bone Marrow Rescue for Recurrent Medulloblastoma and Germ Cell Tumors Completed NCT00002594 Phase 2 cyclophosphamide;melphalan
21 A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children With Recurrent or Refractory Medulloblastoma Completed NCT01239316 Phase 2 Vismodegib
22 Treatment Of Recurrent Central Nervous System Primitive Neuroectodermal Tumors (PNETs) In Children And Adolescents A Strategy Including The Use Of High Dose Thiotepa And High Dose Carboplatin Completed NCT00025077 Phase 2 carboplatin;cyclophosphamide;thiotepa
23 A Phase II Trial of Intravenous Cereport (RMP-7) and Carboplatin in Childhood Brain Tumors Completed NCT00019422 Phase 2 carboplatin;lobradimil
24 Dose Intensive Chemotherapy for Patients Greater Than or Equal To 10 Years of Age With Newly Diagnosed High Stage Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors (PNET) and Ependymoma: A Feasibility Study of an Intensive Induction Chemotherapy Regimen Followed by Standard Irradiation Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
25 A Phase II Trial of Rebeccamycin Analogue (NSC #655649) in Children With Solid Tumors Completed NCT00006102 Phase 2 becatecarin
26 Phase II Treatment of Children With Newly Diagnosed Malignant Central Nervous System Tumors With Temozolomide Prior to Radiation Therapy Completed NCT00005955 Phase 2 temozolomide
27 A Phase I/II Feasibility Study of Oral Etoposide Given Concurrently With Radiotherapy Followed With Dose Intensive Adjuvant Chemotherapy for Children With Newly Diagnosed High Stage Medulloblastoma Completed NCT00003573 Phase 2 cisplatin;cyclophosphamide;etoposide;vincristine sulfate
28 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
29 Phase II Trial Of High Dose Cyclophosphamide, Cisplatin And Carmustine With Stem Cell Reconstitution Followed By Specific Cellular Therapy In Patients With Recurrent Or Refractory Brain Tumors Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
30 Treatment of High Risk Central Nervous System Embryonal Tumors With Conventional Radiotherapy and Intensive Consolidation Chemotherapy With Peripheral Blood Progenitor Cell (PBSC) Support Completed NCT00003846 Phase 2 carboplatin;cyclophosphamide;thiotepa;vincristine sulfate
31 Treatment of Newly Diagnosed Medulloblastoma and Supratentorial PNET in Patients At Least 3 Years With a Phase II Topotecan Window (High-Risk Patients Only), Risk-Adapted Radiation Therapy, and Dose-Intensive Chemotherapy With Peripheral Blood Stem Cell Support Completed NCT00003211 Phase 2 amifostine trihydrate;cisplatin;cyclophosphamide;vincristine sulfate
32 An Intergroup Pilot Study of Concurrent Carboplatin, Vincristine and Radiotherapy Followed by Adjuvant Chemotherapy in Patients With Newly Diagnosed High-Risk Central Nervous System Embryonal Tumors Completed NCT00003203 Phase 2 carboplatin;cisplatin;cyclophosphamide;vincristine sulfate
33 Phase II Study of Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP) as Primary Therapy in Infants or Young Children With Primitive Neuroectodermal Tumors or High-Grade Astrocytoma Completed NCT00002463 Phase 2 MOPP Regimen;Leucovorin Calcium;Mechlorethamine Hydrochloride;Methotrexate;Prednisone;Procarbazine Hydrochloride;Vincristine Sulfate
34 PBTC-053: A Pediatric Brain Tumor Consortium Phase I/ II and Surgical Study of CX-4945 in Patients With Recurrent SHH Medulloblastoma Recruiting NCT03904862 Phase 1, Phase 2 CX 4945
35 A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma Recruiting NCT01878617 Phase 2 Cyclophosphamide;Cisplatin;Vincristine;Vismodegib;Pemetrexed;Gemcitabine
36 A Phase II Study of Intraventricular Methotrexate With Systemic Topotecan and Cyclophosphamide in Children With Recurrent or Progressive Malignant Brain Tumors Active, not recruiting NCT02684071 Phase 2 Intra thecal methotrexate;topotecan;cyclophosphamide
37 Temozolomide With Irinotecan Versus Temozolomide, Irinotecan Plus Bevacizumab (NSC# 704865) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, a COG Randomized Phase II Screening Trial Active, not recruiting NCT01217437 Phase 2 Irinotecan Hydrochloride;Temozolomide
38 Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms Active, not recruiting NCT00445965 Phase 2
39 Dasatinib With Ifosfamide, Carboplatin, Etoposide: A Pediatric Phase I/II Trial Active, not recruiting NCT00788125 Phase 1, Phase 2 carboplatin;dasatinib;etoposide phosphate;ifosfamide
40 Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma Active, not recruiting NCT00602667 Phase 2 Induction Chemotherapy;Low-Risk Therapy;High-Risk Therapy;Intermediate-Risk Therapy
41 A Phase I/II Dose-escalation and Expansion Cohort Trial of Intracerebroventricular Radioimmunotherapy Using 177Lu-DTPA-Omburtamab in Pediatric and Adolescent Patients With Recurrent or Refractory Medulloblastoma Not yet recruiting NCT04167618 Phase 1, Phase 2 177Lu-DTPA-omburtamab
42 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa, Etoposide and Carboplatin) and Autologous Stem Cell Rescue Withdrawn NCT00003273 Phase 2 carboplatin;cisplatin;cyclophosphamide;etoposide;leucovorin calcium;methotrexate;temozolomide;thiotepa;vincristine sulfate
43 Photodynamic Therapy For Childhood Brain Tumors, A Phase I Study Unknown status NCT00002647 Phase 1 verteporfin
44 Phase I Studies of TARCEVA™ (ERLOTINIB HYDROCHLORIDE, OSI-774) as Single Agent in Children With Refractory and Relapsed Malignant Brain Tumors and in Combination With Irradiation in Newly Diagnosed Brain Stem Glioma Unknown status NCT00360854 Phase 1 erlotinib hydrochloride
45 Phase I Study of Doxorubicin HCl Liposome in Pediatric Patients With Refractory Solid Tumors Completed NCT00019630 Phase 1 doxorubicin HCl liposome
46 Phase I and Pharmacokinetic Study of Enzastaurin (LY317615) in Children and Adolescents With Refractory Primary CNS Tumors Completed NCT00503724 Phase 1 enzastaurin hydrochloride
47 A Phase I Dose Escalation Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Pediatric Patients With Advanced Solid Tumors and Lymphomas Completed NCT00004212 Phase 1 exatecan mesylate
48 A Phase I Pharmacokinetic and Safety Study in Children With Recurrent or Refractory Medulloblastoma to Identify a Pharmacokinetic Based Dose for GDC-0449 Completed NCT00822458 Phase 1 vismodegib
49 Phase I Trial Of Escalating Oral Doses Of SCH 66336 In Pediatric Patients With Refractory Or Recurrent Brain Tumors Completed NCT00015899 Phase 1 lonafarnib
50 High Dose Carboplatin Combined With Oral VP-16 In The Treatment Of Pediatric CNS Malignancies Completed NCT00053118 Phase 1 carboplatin;etoposide

Search NIH Clinical Center for Childhood Medulloblastoma

Genetic Tests for Childhood Medulloblastoma

Anatomical Context for Childhood Medulloblastoma

MalaCards organs/tissues related to Childhood Medulloblastoma:

40
Brain, Breast, Lung, Bone, Ovary, Thyroid, Liver

Publications for Childhood Medulloblastoma

Articles related to Childhood Medulloblastoma:

(show top 50) (show all 209)
# Title Authors PMID Year
1
Disabling c-Myc in childhood medulloblastoma and atypical teratoid/rhabdoid tumor cells by the potent G-quadruplex interactive agent S2T1-6OTD. 54 61
20053783 2010
2
RNA interference-mediated c-MYC inhibition prevents cell growth and decreases sensitivity to radio- and chemotherapy in childhood medulloblastoma cells. 54 61
19134217 2009
3
Expression of the ErbB-neuregulin signaling network during human cerebellar development: implications for the biology of medulloblastoma. 54 61
9731505 1998
4
Expression of the c-Myc protein in childhood medulloblastoma. 54 61
9482408 1998
5
Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. 54 61
9242460 1997
6
Germline GPR161 Mutations Predispose to Pediatric Medulloblastoma. 61
31609649 2020
7
Strategy to minimize radiation burden in infants and high-risk medulloblastoma using intrathecal methotrexate and high-dose chemotherapy: A prospective registry study in Japan. 61
31544362 2020
8
[Subgroup-specific genomic alterations and potential prognostic biomarkers in childhood medulloblastomas]. 61
31821388 2019
9
Childhood medulloblastoma-a single institution's historical perspective on survival and functional morbidity. 61
31686139 2019
10
Salvage Therapy for Childhood Medulloblastoma: A Single Center Experience. 61
31293232 2019
11
Twenty years experience in treating childhood medulloblastoma: Between the past and the present. 61
31109839 2019
12
Intellectual, educational, and situation-based social outcome in adult survivors of childhood medulloblastoma. 61
29336639 2019
13
Survival and prognostic factors in childhood medulloblastoma: A Brazilian single center experience from 1995 to 2016. 61
31528456 2019
14
Childhood Medulloblastoma Revisited. 61
30516696 2018
15
Pneumolabyrinth, intracochlear and vestibular fluid loss after cochlear implantation. 61
29680680 2018
16
Mutations in SUFU and PTCH1 genes may cause different cutaneous cancer predisposition syndromes: similar, but not the same. 61
29356994 2018
17
National cancer registry and broad institutional cooperation: turning points in treating childhood medulloblastoma in Iran. 61
29804211 2018
18
Study on Contribution of Biological Interpretable and Computer-Aided Features Towards the Classification of Childhood Medulloblastoma Cells. 61
29974336 2018
19
Neuropsychological consequences of childhood medulloblastoma and possible interventions: A review. 61
29716738 2018
20
Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights. 61
29189165 2018
21
Low- and middle-income countries can reduce risks of subsequent neoplasms by referring pediatric craniospinal cases to centralized proton treatment centers. 61
30038799 2018
22
First evidence of genotype-phenotype correlations in Gorlin syndrome. 61
28596197 2017
23
Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. 61
28545823 2017
24
Core deficits and quality of survival after childhood medulloblastoma: a review. 61
31385962 2017
25
Long-term neurologic health and psychosocial function of adult survivors of childhood medulloblastoma/PNET: a report from the Childhood Cancer Survivor Study. 61
28039368 2017
26
Challenges of Treating Childhood Medulloblastoma in a Country With Limited Resources: 20 Years of Experience at a Single Tertiary Center in Malaysia. 61
28717752 2017
27
Survival in pediatric medulloblastoma: a population-based observational study to improve prognostication. 61
27981412 2017
28
The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma. 61
27785591 2017
29
Erratum to: The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma. 61
27900530 2017
30
Long-term safety of growth hormone replacement therapy after childhood medulloblastoma and PNET: it is time to set aside old concerns. 61
27770281 2017
31
Neurocognitive Function and Health-Related Quality of Life in Pediatric Korean Survivors of Medulloblastoma. 61
27709849 2016
32
Childhood medulloblastoma. 61
27375228 2016
33
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. 61
27040285 2016
34
Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses. 61
26188016 2016
35
Evolving molecular era of childhood medulloblastoma: time to revisit therapy. 61
26617331 2016
36
Effect of motivation on academic fluency performance in survivors of pediatric medulloblastoma. 61
25825959 2016
37
SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastoma. 61
26400460 2015
38
The use of 5-ALA to assist complete removal of residual non-enhancing part of childhood medulloblastoma: a case report. 61
26070965 2015
39
CCND2, CTNNB1, DDX3X, GLI2, SMARCA4, MYC, MYCN, PTCH1, TP53, and MLL2 gene variants and risk of childhood medulloblastoma. 61
26290144 2015
40
Evidence of high mortality in long term survivors of childhood medulloblastoma. 61
25557108 2015
41
Ovarian function in survivors of childhood medulloblastoma: Impact of reduced dose craniospinal irradiation and high-dose chemotherapy with autologous stem cell rescue. 61
25346052 2015
42
A rare case of medulloblastoma coexisting with multiple spinal intramedullary tumors. 61
25832201 2015
43
School Competence and Fluent Academic Performance: Informing Assessment of Educational Outcomes in Survivors of Pediatric Medulloblastoma. 61
25398080 2015
44
Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations. 61
25403219 2014
45
Duration of the pre-diagnostic interval in medulloblastoma is subgroup dependent. 61
24616042 2014
46
Treatment developments and the unfolding of the quality of life discussion in childhood medulloblastoma: a review. 61
24569911 2014
47
NOTCH ligands JAG1 and JAG2 as critical pro-survival factors in childhood medulloblastoma. 61
24708907 2014
48
The biologic era of childhood medulloblastoma and clues to novel therapies. 61
24754593 2014
49
Hepatic sinusoidal obstruction syndrome during chemotherapy for childhood medulloblastoma: report of a case and review of the literature. 61
24276042 2014
50
Increased focal hemosiderin deposition in pediatric medulloblastoma patients receiving radiotherapy at a later age. 61
23992236 2013

Variations for Childhood Medulloblastoma

Expression for Childhood Medulloblastoma

Search GEO for disease gene expression data for Childhood Medulloblastoma.

Pathways for Childhood Medulloblastoma

Pathways related to Childhood Medulloblastoma according to GeneCards Suite gene sharing:

(show top 50) (show all 88)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.21 TP53 TERT SUFU SMARCA4 PTCH1 PDGFRA
2
Show member pathways
14.1 TP53 SMARCA4 PDGFRA MYC ERBB4 ERBB3
3
Show member pathways
13.84 TP53 SUFU PTCH1 PDGFRA NTRK3 MYC
4
Show member pathways
13.77 TP53 PDGFRA NTRK3 MYC ERBB4 ERBB3
5
Show member pathways
13.75 TP53 SMARCA4 PDGFRA NTRK3 MYC ERBB4
6
Show member pathways
13.62 SUFU PTCH1 PDGFRA NTRK3 ERBB4 ERBB3
7
Show member pathways
13.6 TP53 PDGFRA NTRK3 MYC ERBB4 ERBB3
8
Show member pathways
13.48 TP53 PDGFRA NTRK3 ERBB4 ERBB3 ERBB2
9
Show member pathways
13.43 TP53 SMARCA4 PDGFRA MYC ERBB4 ERBB3
10
Show member pathways
13.34 PDGFRA NTRK3 ERBB4 ERBB3 ERBB2 EGFR
11
Show member pathways
13.28 TP53 MYC ERBB4 ERBB3 ERBB2 EGFR
12
Show member pathways
13.18 TP53 MYC EGFR DDX3X CTNNB1 CCND1
13
Show member pathways
13.17 TP53 PDGFRA ERBB4 ERBB3 ERBB2 EGFR
14
Show member pathways
13.01 TP53 PDGFRA MYC EGFR CTNNB1 CCND1
15
Show member pathways
13.01 PDGFRA NTRK3 ERBB4 ERBB3 ERBB2 EGFR
16
Show member pathways
12.95 TP53 PDGFRA MYC ERBB2 EGFR CTNNB1
17
Show member pathways
12.94 TP53 TERT PDGFRA MYC ERBB4 ERBB3
18
Show member pathways
12.93 PDGFRA NTRK3 ERBB4 ERBB3 ERBB2 EGFR
19 12.82 TP53 PDGFRA MYC ERBB4 ERBB3 ERBB2
20
Show member pathways
12.81 TP53 PDGFRA ERBB4 ERBB3 ERBB2 EGFR
21
Show member pathways
12.78 TP53 NTRK3 ERBB3 ERBB2 CTNNB1
22
Show member pathways
12.76 TP53 TERT SMARCA4 MYC ERBB2 EGFR
23
Show member pathways
12.75 TP53 PDGFRA ERBB3 ERBB2 EGFR CCND1
24
Show member pathways
12.67 TP53 PDGFRA MYC ERBB2 EGFR CTNNB1
25
Show member pathways
12.59 TP53 PDGFRA MYC ERBB4 ERBB3 ERBB2
26
Show member pathways
12.58 TP53 SUFU PTCH1 MYC GLI2 CTNNB1
27
Show member pathways
12.57 TP53 PDGFRA ERBB4 ERBB3 ERBB2 EGFR
28 12.57 TP53 PDGFRA MYC ERBB3 ERBB2 EGFR
29
Show member pathways
12.52 TP53 MYC ERBB4 ERBB3 ERBB2 EGFR
30 12.5 TP53 SMARCA4 MYC CTNNB1 CCND1
31
Show member pathways
12.46 PDGFRA NTRK3 ERBB4 ERBB3 ERBB2 EGFR
32 12.42 TP53 TERT SUFU PTCH1 PDGFRA MYC
33
Show member pathways
12.41 PDGFRA MYC EGFR CCND1
34
Show member pathways
12.41 PDGFRA ERBB3 ERBB2 EGFR CCND1
35 12.4 TP53 TERT MYC CCND1
36
Show member pathways
12.37 PDGFRA ERBB4 ERBB3 ERBB2 EGFR
37
Show member pathways
12.36 ERBB4 ERBB3 ERBB2 EGFR
38
Show member pathways
12.35 TP53 TERT PDGFRA NTRK3 MYC EGFR
39
Show member pathways
12.35 TP53 PDGFRA NTRK3 ERBB4 ERBB3 ERBB2
40 12.31 SUFU PTCH1 GLI2 CTNNB1
41
Show member pathways
12.3 TP53 MYC CTNNB1 CCND1
42 12.27 TP53 MYC EGFR CTNNB1 CCND1
43 12.22 MYC GLI2 CTNNB1 CCND1
44
Show member pathways
12.21 PDGFRA MYC ERBB2 EGFR
45 12.21 PDGFRA ERBB4 ERBB3 ERBB2 EGFR
46
Show member pathways
12.19 ERBB2 EGFR CTNNB1 CCND1
47 12.17 TP53 SMARCA4 MYC EGFR CTNNB1 CCND1
48 12.14 TP53 TERT MYC CCND1
49
Show member pathways
12.12 ERBB4 ERBB3 ERBB2 EGFR CCND1
50 12.09 TP53 MYC EGFR CCND1

GO Terms for Childhood Medulloblastoma

Cellular components related to Childhood Medulloblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 10.09 TP53 TERT SUFU SMARCA4 PTCH1 PDGFRA
2 nucleoplasm GO:0005654 10.07 TP53 TERT SUFU SMARCA4 PDGFRA MYCN
3 nucleolus GO:0005730 9.88 TP53 TERT SMARCA4 MYCN MYC GLI2
4 protein-containing complex GO:0032991 9.85 TP53 SMARCA4 PDGFRA MYC EGFR CTNNB1
5 basolateral plasma membrane GO:0016323 9.72 ERBB4 ERBB3 ERBB2 EGFR CTNNB1
6 basal plasma membrane GO:0009925 9.26 ERBB4 ERBB3 ERBB2 EGFR
7 receptor complex GO:0043235 9.1 PDGFRA NTRK3 ERBB4 ERBB3 ERBB2 EGFR

Biological processes related to Childhood Medulloblastoma according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Name GO ID Score Top Affiliating Genes
1 multicellular organism development GO:0007275 10.24 TP53 SUFU PDGFRA NTRK3 GLI2 ERBB4
2 cell differentiation GO:0030154 10.22 TP53 NTRK3 GLI2 EGFR DDX3X CTNNB1
3 positive regulation of transcription by RNA polymerase II GO:0045944 10.19 TP53 SMARCA4 MYCN MYC KMT2D GLI2
4 phosphorylation GO:0016310 10.17 PDGFRA NTRK3 ERBB4 ERBB3 ERBB2 EGFR
5 regulation of transcription by RNA polymerase II GO:0006357 10.16 TP53 SMARCA4 MYCN MYC ERBB2 EGFR
6 negative regulation of transcription by RNA polymerase II GO:0000122 10.15 TP53 SUFU SMARCA4 PTCH1 MYC GLI2
7 protein phosphorylation GO:0006468 10.14 PDGFRA NTRK3 ERBB4 ERBB3 ERBB2 EGFR
8 nervous system development GO:0007399 10.12 SMARCA4 NTRK3 ERBB4 ERBB3 ERBB2 CTNNB1
9 negative regulation of apoptotic process GO:0043066 10.11 TP53 TERT MYC GLI2 EGFR DDX3X
10 response to drug GO:0042493 10.06 TP53 PTCH1 MYC CTNNB1 CCND1
11 in utero embryonic development GO:0001701 10.02 TP53 PTCH1 PDGFRA GLI2 CTNNB1
12 cell proliferation GO:0008283 10.01 TP53 GLI2 EGFR CTNNB1
13 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.01 PDGFRA NTRK3 ERBB4 EGFR
14 positive regulation of gene expression GO:0010628 10.01 TP53 NTRK3 MYCN MYC ERBB3 ERBB2
15 regulation of cell proliferation GO:0042127 10 TP53 PTCH1 ERBB3 EGFR CTNNB1
16 protein autophosphorylation GO:0046777 9.99 PDGFRA ERBB4 ERBB2 EGFR
17 positive regulation of protein phosphorylation GO:0001934 9.99 NTRK3 ERBB4 ERBB2 EGFR CCND1
18 positive regulation of protein kinase B signaling GO:0051897 9.98 PDGFRA ERBB4 ERBB3 ERBB2 EGFR
19 MAPK cascade GO:0000165 9.97 PDGFRA MYC ERBB4 ERBB3 ERBB2 EGFR
20 response to estradiol GO:0032355 9.93 PTCH1 EGFR CTNNB1 CCND1
21 lung development GO:0030324 9.92 PDGFRA GLI2 EGFR CTNNB1
22 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.91 PDGFRA NTRK3 ERBB4 ERBB3
23 positive regulation of transcription, DNA-templated GO:0045893 9.91 TP53 SMARCA4 PTCH1 MYCN MYC GLI2
24 positive regulation of cell growth GO:0030307 9.89 ERBB2 EGFR DDX3X
25 positive regulation of translation GO:0045727 9.89 MYC ERBB2 DDX3X
26 cellular response to growth factor stimulus GO:0071363 9.88 ERBB2 EGFR CTNNB1
27 cellular response to drug GO:0035690 9.88 TP53 MYC EGFR
28 positive regulation of epithelial cell proliferation GO:0050679 9.88 MYC ERBB2 EGFR CCND1
29 wound healing GO:0042060 9.88 TP53 PDGFRA ERBB3 ERBB2 EGFR
30 odontogenesis of dentin-containing tooth GO:0042475 9.87 PDGFRA GLI2 CTNNB1
31 heart development GO:0007507 9.87 TP53 NTRK3 GLI2 ERBB4 ERBB3 ERBB2
32 positive regulation of fibroblast proliferation GO:0048146 9.86 PDGFRA MYC EGFR
33 cellular response to epidermal growth factor stimulus GO:0071364 9.85 ERBB4 ERBB2 EGFR
34 branching involved in ureteric bud morphogenesis GO:0001658 9.85 PTCH1 MYC CTNNB1
35 peptidyl-tyrosine phosphorylation GO:0018108 9.85 PDGFRA NTRK3 ERBB4 ERBB3 ERBB2 EGFR
36 dorsal/ventral pattern formation GO:0009953 9.84 PTCH1 GLI2 CTNNB1
37 cellular response to reactive oxygen species GO:0034614 9.84 TP53 PDGFRA EGFR
38 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.81 TP53 TERT SMARCA4
39 liver regeneration GO:0097421 9.81 PTCH1 EGFR CCND1
40 positive regulation of G1/S transition of mitotic cell cycle GO:1900087 9.81 TERT EGFR DDX3X CCND1
41 regulation of cell motility GO:2000145 9.76 ERBB4 ERBB3 ERBB2 EGFR
42 ERBB2 signaling pathway GO:0038128 9.73 ERBB4 ERBB3 ERBB2 EGFR
43 Leydig cell differentiation GO:0033327 9.72 PDGFRA CCND1
44 negative regulation of cell division GO:0051782 9.71 PTCH1 MYC
45 mitotic G1 DNA damage checkpoint GO:0031571 9.7 TP53 CCND1
46 smoothened signaling pathway involved in dorsal/ventral neural tube patterning GO:0060831 9.7 PTCH1 GLI2
47 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.7 TP53 MYCN EGFR
48 negative regulation of ERBB signaling pathway GO:1901185 9.69 ERBB2 EGFR
49 mammary gland duct morphogenesis GO:0060603 9.68 PTCH1 GLI2
50 spinal cord dorsal/ventral patterning GO:0021513 9.68 SUFU GLI2

Molecular functions related to Childhood Medulloblastoma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.35 TP53 TERT SUFU SMARCA4 PTCH1 PDGFRA
2 DNA binding GO:0003677 10.18 TP53 TERT SMARCA4 MYCN MYC KMT2D
3 transferase activity GO:0016740 10.16 TERT PDGFRA NTRK3 KMT2D ERBB4 ERBB3
4 ATP binding GO:0005524 10.11 TP53 SMARCA4 PDGFRA NTRK3 ERBB4 ERBB3
5 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.95 TP53 SMARCA4 MYCN MYC GLI2 BATF2
6 kinase activity GO:0016301 9.95 PDGFRA NTRK3 ERBB4 ERBB3 ERBB2 EGFR
7 protein kinase binding GO:0019901 9.93 TP53 SUFU EGFR CTNNB1 CCND1
8 transcription regulatory region DNA binding GO:0044212 9.85 TP53 KMT2D GLI2 ERBB4
9 protein C-terminus binding GO:0008022 9.8 TP53 TERT ERBB2 CTNNB1
10 nucleotide binding GO:0000166 9.8 SMARCA4 PDGFRA ERBB4 ERBB3 ERBB2 EGFR
11 protein kinase activity GO:0004672 9.8 PDGFRA NTRK3 ERBB4 ERBB3 ERBB2 EGFR
12 protein phosphatase binding GO:0019903 9.73 TP53 ERBB2 EGFR CTNNB1
13 p53 binding GO:0002039 9.69 TP53 SMARCA4 NTRK3
14 protein tyrosine kinase activity GO:0004713 9.63 PDGFRA NTRK3 ERBB4 ERBB3 ERBB2 EGFR
15 transcription factor binding GO:0008134 9.56 TP53 SUFU SMARCA4 MYC GLI2 DDX3X
16 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.1 PDGFRA NTRK3 ERBB4 ERBB3 ERBB2 EGFR

Sources for Childhood Medulloblastoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....